Abstract
AbstractThe liver carries out many essential tasks, such as synthesising cholesterol, controlling the body’s storage of glycogen, and detoxifying metabolites, in addition to performing, and regulating homeostasis. Hepatic fibrosis is a pathological state characterized by over accumulation of extracellular matrix (ECM) including collagen fibers. Sildenafil (a selective inhibitor of type 5 phosphodiesterase) has anti-inflammatory, antioxidant and anti-apoptotic properties. It is commonly used to treat erectile dysfunction in male. The purpose of the current investigation was to evaluate sildenafil’s hepatoprotective potential against liver fibrosis in rats that was caused by carbon tetrachloride (CCl4). Liver enzymes and oxidative markers as well as profibrotic genes were determined. The findings showed that sildenafil alleviates the hepatic dysfunctions caused by CCl4 by restoring normal levels of ALT, AST, and GGT as well as by restoring the antioxidant status demonstrated by increased glutathione (GSH), and catalase. In addition, a significantly down-regulated the mRNA expressions of profibrotic genes [collagen-1α, IL-1β, osteopontin (OPN), and transforming growth factor-β (TGF-β)]. Additionally, sildenafil lessens the periportal fibrosis between hepatic lobules, congestion and dilatation in the central vein, and the inflammatory cell infiltrations. As a result, it is hypothesized that sildenafil may be helpful in the management of hepatotoxicity brought on by CCl4 through suppressing OPN.
Publisher
Springer Science and Business Media LLC
Reference52 articles.
1. Zhao, T. et al. Regulating Nrf2-GPx4 axis by bicyclol can prevent ferroptosis in carbon tetrachloride-induced acute liver injury in mice. Cell Death Discov. 8(1), 380 (2022).
2. Long, X. et al. Preventive effect of Lactobacillus plantarum HFY15 on carbon tetrachloride (CCl4)-induced acute liver injury in mice. J. Food Sci. 87(6), 2626–2639 (2022).
3. Zhang, X. et al. Targeting hepatic stellate cell death to reverse hepatic fibrosis. Curr. Drug Targets 24(7), 568–583 (2023).
4. Nianan, L., Jiangbin, L., Yu, W., Jianguo, L. & Rui, D. Hepatic stellate cell: A double-edged sword in the liver. Physiol. Res. 70(6), 821 (2021).
5. Zhao, T. et al. Effect of ADHI on hepatic stellate cell activation and liver fibrosis in mice. Biochem. Biophys. Res. Commun. 651, 98–106 (2023).